Trial · NCT03357757
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of Avelumab and VPA | 1 year after enrolment of last patient | • Assessment of the clinical response rate according to the immune-related RECIST criteria (iRECIST) |
| Primary | Proportion of subjects who complete 4 doses of Avelumab in combination with VPA | 1 year after enrolment of last patient | • Feasibility analysis, defined as the proportion of subjects who complete 4 doses of Avelumab in combination with VPA over the total duration of the study. |
| Secondary | Overall survival | 5 years from final study drug dose | defined as the time from the date of enrollment to the date of death, whatever the cause. |
| Secondary | Progression free survival | 5 years from final study drug dose | Progression free survival is defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause), whichever occurs first. |
| Secondary | Number of participants with adverse events | Through study completion, up to 2 years | • Incidence of adverse events (assessed as the incidence and severity of adverse events, including immune-related adverse events, and the number of discontinuations due to adverse events). |
| Secondary | Identify specific virus-associated cancers as candidates for subsequent study | Through study completion, up to 2 years | |
| Secondary | Measurement of Immuno-score | Through study completion, up to 2 years | AffymetriX Micro-array (Immuno-score) |
| Secondary | Measurement of MHC expression | Through study completion, up to 2 years | |
| Secondary | Measurement of cell-free tumoral DNA in blood | Through study completion, up to 2 years | |
| Secondary | Phenotyping of Tumour Infiltrating Lymphocytes | Through study completion, up to 2 years | |
| Secondary | DNA viral load | Through study completion, up to 2 years | DNA Quantitative PCR (viral load) |
| Secondary | Expression of lytic viral genes | Through study completion, up to 2 years | |
| Secondary | Cytotoxic T-Lymphocyte immunophenotyping | Through study completion, up to 2 years | |
| Secondary | T-cell receptor sequencing | Through study completion, up to 2 years | |
| Secondary | Hsp90 concentration in serum | Through study completion, up to 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03357757/registered